ArticleArchives of medical science : AMS2023
A look to the past - what has had the biggest impact on lipids in the last four decades? A personal perspective.
Article in Archives of medical science : AMS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- A natural small molecule isoginkgetin alleviates hypercholesterolemia and atherosclerosis by targeting ACLY.Theranostics · 2025Article
- Updated focused review of hematological, inflammatory, and lipid biomarkers in acute coronary syndrome.Archives of medical science : AMS · 2025Article
- 2024 update on postmarketing nutrivigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia.Archives of medical science : AMS · 2025Article
- Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025.Archives of medical science : AMS · 2025Article
- Treatment of dyslipidemia in Poland - common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot.Cardiology journal · 2025Article
- Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia.Cell reports. Medicine · 2024Article
- Dyslipidaemia management in pregnant patients: a 2024 update.European heart journal open · 2024Review
- Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?Current atherosclerosis reports · 2024Review
- Efficacy of statin therapy in reducing epicardial adipose tissue: a systematic review and meta-analysis.Archives of medical science : AMS · 2024Article
- Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and methodology.Archives of medical science : AMS · 2024Article
- Summary of 2023 and the biggest challenges for the "Archives of Medical Science" on its 20Archives of medical science : AMS · 2024Article
- Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association.Archives of medical science : AMS · 2024Article
- Nutrition, Nutraceuticals and Bioactive Compounds in the Prevention and Fight against Inflammation.Nutrients · 2023Article
- 2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?Archives of medical science : AMS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.